Lilly makes another move for Verve's genetic medicines, this time buying Beam's opt-in rights - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Eli Lilly is once again tapping into Verve Therapeutics, which is developing one-time treatments in the cardiovascular disease space, as the pharma giant continues to beef up its research into genetic medicines. This time, Lilly is betting on Verve’s pipeline…